0001714899-21-000107.txt : 20211108
0001714899-21-000107.hdr.sgml : 20211108
20211108161617
ACCESSION NUMBER: 0001714899-21-000107
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211104
FILED AS OF DATE: 20211108
DATE AS OF CHANGE: 20211108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schuth Alexander O.
CENTRAL INDEX KEY: 0001724311
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 211388172
MAIL ADDRESS:
STREET 1: C/O DENALI THERAPEUTICS INC.
STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wf-form4_163640615125307.xml
FORM 4
X0306
4
2021-11-04
0
0001714899
Denali Therapeutics Inc.
DNLI
0001724311
Schuth Alexander O.
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
COO and Secretary
Common Stock
2021-11-04
4
S
0
6717
52.65
D
466366
I
See footnote
Common Stock
2021-11-04
4
S
0
3283
53.23
D
463083
I
See footnote
Common Stock
86454
D
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $51.93 to $52.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $52.94 to $53.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 75,358 restricted stock units.
/s/ Tyler Nielsen, by power of attorney
2021-11-08